z-logo
Premium
Invasive Pneumococcal Infections in Adult Lung Transplant Recipients
Author(s) -
Bruyn Guy de,
Whelan Timothy P.,
Mulligan Michael S.,
Raghu Ganesh,
Limaye Ajit P.
Publication year - 2004
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2004.00512.x
Subject(s) - medicine , incidence (geometry) , retrospective cohort study , epidemiology , pneumococcal polysaccharide vaccine , pneumococcal infections , kidney transplantation , trimethoprim , lung transplantation , transplantation , cohort , lung , streptococcus pneumoniae , intensive care medicine , pneumococcal disease , antibiotics , microbiology and biotechnology , physics , optics , biology
An increased risk of invasive pneumococcal infection (IPI) has been described among kidney or heart transplant recipients, but the epidemiology of IPI among lung transplant recipients has not been previously reported. We undertook a single center, retrospective cohort study to define the incidence, timing, clinical, and microbiologic features of IPI in lung transplant patients. Fourteen out of 220 recipients (6.4%) developed IPI at a median of 1.3 years after transplantation (incidence rate: 22.7 cases per 1000 person‐years). All patients were receiving trimethoprim‐sulfamethoxazole (TMP‐SMX) prophylaxis at the time of diagnosis, and 10 (71%) had TMP‐SMX‐resistant isolates. All isolates were from the 23 valent polysaccharide vaccine‐associated serogroups. The high incidence of IPI in lung transplant recipients is similar to that reported in kidney and heart recipients. Alternative prevention strategies, including use of the conjugated pneumococcal vaccine, should be explored in future studies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here